- Home
- CABA vs FENC Comparison
CABA vs FENC Comparison
Compare CABA & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABA | FENC |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 263.3M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CABA | FENC |
|---|---|---|
| Price | $2.94 | $7.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $14.57 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 2.3M | 123.3K |
| Earning Date | 03-16-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 96.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $47,538,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.69 |
| 52 Week Low | $0.99 | $4.68 |
| 52 Week High | $3.78 | $9.92 |
Technical Indicators
Market Signals| Indicator | CABA | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 40.02 |
| Support Level | $2.11 | $7.44 |
| Resistance Level | $3.34 | $8.27 |
| Average True Range (ATR) | 0.21 | 0.44 |
| MACD | -0.06 | -0.09 |
| Stochastic Oscillator | 18.33 | 9.83 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.